Holen Sie sich die Stockscreener-App
12.81
2.23%
0.28
Handel nachbörslich:
14.50
1.69
+13.19%
Schlusskurs vom Vortag:
$12.53
Offen:
$12.21
24-Stunden-Volumen:
605.35K
Relative Volume:
0.79
Marktkapitalisierung:
$939.47M
Einnahmen:
$125.58M
Nettoeinkommen (Verlust:
$-92.14M
KGV:
-10.31
EPS:
-1.2424
Netto-Cashflow:
$-138.27M
1W Leistung:
+4.06%
1M Leistung:
+4.15%
6M Leistung:
+8.38%
1J Leistung:
+30.45%
1-Tages-Spanne:
$12.20
$12.82
1-Wochen-Bereich:
$10.96
$12.82
52-Wochen-Spanne:
$6.92
$18.69
Xencor Inc Stock (XNCR) Company Profile
Firmenname
Xencor Inc
Sektor
Branche
Telefon
626-305-5900
Adresse
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
12.81 | 939.47M | 125.58M | -92.14M | -138.27M | -1.2424 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-29 | Hochstufung | Barclays | Underweight → Overweight |
| 2025-09-17 | Fortgesetzt | Barclays | Underweight |
| 2025-09-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-04-21 | Eingeleitet | William Blair | Outperform |
| 2024-12-12 | Eingeleitet | Wells Fargo | Overweight |
| 2024-12-02 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-16 | Bestätigt | BTIG Research | Buy |
| 2024-02-28 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2023-05-19 | Eingeleitet | BofA Securities | Buy |
| 2022-12-06 | Eingeleitet | Cowen | Outperform |
| 2022-10-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-06 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-02-11 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-21 | Eingeleitet | SMBC Nikko | Outperform |
| 2021-12-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-02-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Underweight |
| 2020-02-25 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-01-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-11-20 | Fortgesetzt | Guggenheim | Neutral |
| 2019-08-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-08-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-04-12 | Eingeleitet | Guggenheim | Buy |
| 2019-03-27 | Eingeleitet | Berenberg | Buy |
| 2019-03-15 | Eingeleitet | Raymond James | Outperform |
| 2018-09-10 | Fortgesetzt | BTIG Research | Buy |
| 2018-03-28 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Neutral |
| 2017-03-02 | Bestätigt | Wedbush | Outperform |
| 2016-10-04 | Eingeleitet | Piper Jaffray | Overweight |
| 2015-12-22 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-08-05 | Bestätigt | MLV & Co | Buy |
| 2015-02-12 | Bestätigt | Oppenheimer | Outperform |
| 2015-01-28 | Bestätigt | MLV & Co | Buy |
| 2014-07-11 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Xencor Inc Aktie (XNCR) Neueste Nachrichten
Xencor sr. VP Desjarlais sells $31,676 in stock - Investing.com
Dahiyat, Xencor CEO, sells $80k in XNCR stock - Investing.com
Xencor SVP Eckert sells $17,747 in shares - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Below 200-Day Moving AverageWhat's Next? - MarketBeat
Aug Weekly: Can Xencor Inc expand its profit marginsRate Hike & Daily Profit Focused Screening - baoquankhu1.vn
RA Capital, insiders report shared 6.5% stake in Xencor (NASDAQ: XNCR) - Stock Titan
Big Money Moves: What is the long term forecast for Xencor Inc stock2026 Review & Breakout Confirmation Trade Signals - baoquankhu1.vn
Pharma News: What is the target price for Xencor Inc stock2026 Geopolitical Influence & Reliable Intraday Trade Plans - baoquankhu1.vn
Portfolio Recap: What is the long term forecast for Xencor Inc stockMarket Performance Report & Weekly Top Performers Watchlists - baoquankhu1.vn
Investment Recap: Should you buy the dip on Xencor Inc2026 Momentum Check & Safe Entry Trade Reports - baoquankhu1.vn
Value Recap: Can Xencor Inc disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Vanguard (XNCR) reports 0 shares after internal realignment amendment - Stock Titan
Aug Levels: Is Xencor Inc stock showing strong momentumMarket Performance Report & Verified Technical Signals - baoquankhu1.vn
Buyout Rumor: Is Xencor Inc a top pick in the sectorMarket Risk Analysis & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Earnings Beat: Is Xencor Inc stock a good pick for beginnersWeekly Profit Analysis & Weekly Consistent Profit Watchlists - baoquankhu1.vn
Aug Sentiment: Should value investors consider Xencor Inc2026 Drop Watch & Consistent Income Trade Ideas - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA) and Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Shares Gap DownTime to Sell? - marketbeat.com
JPMorgan Chase & Co. Reiterates Neutral Rating for Xencor (NASDAQ:XNCR) - MarketBeat
Xencor stock downgraded to neutral at JPMorgan on execution concerns By Investing.com - Investing.com Australia
JPMorgan Downgrades Xencor to Neutral From Overweight, Adjusts PT to $13 From $18 - MarketScreener
Xencor stock downgraded to neutral at JPMorgan on execution concerns - Investing.com
Xencor (NASDAQ:XNCR) Shares Cross Above Fifty Day Moving AverageHere's What Happened - MarketBeat
How Xencor Inc. (XNCR) Affects Rotational Strategy Timing - Stock Traders Daily
XNCR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Analyst Upgrade: What is the Moat Score of Xencor Inc2026 Selloffs & Capital Protection Trade Alerts - baoquankhu1.vn
Aug Analyst Calls: What hedge funds are buying Xencor IncLong Setup & Daily Price Action Insights - baoquankhu1.vn
Macro Review: Will Xencor Inc stock hit new highs in YEAR2026 Top Decliners & Fast Momentum Entry Tips - baoquankhu1.vn
Royalty rift: Alexion cuts off US royalty payments to Xencor - MSN
Retail Trends: Can Xencor Inc beat the S P 500Quarterly Growth Report & Expert Curated Trade Ideas - baoquankhu1.vn
Earnings Recap: Is Xencor Inc backed by strong institutional buying2026 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
Braidwell LP Lowers Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor, Inc. $XNCR Shares Purchased by Baker BROS. Advisors LP - MarketBeat
Xencor’s Lung Cancer Trial Halted: What the Vudalimab Update Means for XNCR Investors - The Globe and Mail
Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR - MarketBeat
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans By Investing.com - Investing.com India
Xencor at Barclays Healthcare Conference: Pipeline Progress and Strategic Plans - Investing.com Australia
(XNCR) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Xencor at Leerink Global Healthcare: Strategic Development Insights - Investing.com Nigeria
Xencor, Inc. (NASDAQ:XNCR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Xencor faces royalty dispute with Alexion over Ultomiris sales - Investing.com Nigeria
Xencor (NASDAQ:XNCR) CEO Sells $72,798.12 in Stock - MarketBeat
John Desjarlais Sells 4,118 Shares of Xencor (NASDAQ:XNCR) Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Sells $19,472.34 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 3,244 Shares - MarketBeat
Xencor (NASDAQ:XNCR) VP Sells $27,572.04 in Stock - MarketBeat
Xencor (NASDAQ:XNCR) CEO Bassil Dahiyat Sells 14,870 Shares - MarketBeat
Xencor, Genentech to End Protein Therapeutics Collaboration - TipRanks
Xencor (XNCR) SVP and general counsel sells 5,011 shares for RSU tax - Stock Titan
Xencor (XNCR) CFO sells 2,517 shares to cover RSU tax withholding - Stock Titan
Xencor (XNCR) CEO sells 21,476 shares to cover RSU tax obligations - Stock Titan
Finanzdaten der Xencor Inc-Aktie (XNCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Xencor Inc-Aktie (XNCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Mar 06 '26 |
Sale |
11.02 |
2,502 |
27,571 |
263,831 |
| Eckert Celia | SVP, GENERAL COUNSEL |
Mar 05 '26 |
Sale |
11.25 |
3,244 |
36,480 |
78,685 |
| Eckert Celia | SVP, GENERAL COUNSEL |
Mar 06 '26 |
Sale |
11.02 |
1,767 |
19,472 |
76,918 |
| Cornelissen Bart Jan | SR. VICE PRESIDENT & CFO |
Mar 05 '26 |
Sale |
11.25 |
2,517 |
28,305 |
79,397 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Mar 05 '26 |
Sale |
11.25 |
14,870 |
167,221 |
552,922 |
| Dahiyat Bassil I | PRESIDENT & CEO |
Mar 06 '26 |
Sale |
11.02 |
6,606 |
72,796 |
546,316 |
0.49%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):